25rhk215 10.3205/25rhk215 urn:nbn:de:0183-25rhk2159 Meeting Abstract Kvacskay Kvacskay Peter P

Department Innere Medizin/Klinik für Hämatologie, Onkologie und Rheumatologie, Heidelberg

author Buschulte Buschulte Katharina K

Thoraxklinik Heidelberg gGmbH, Universitätsklinikum Heidelberg, Heidelberg

author Blank Blank Norbert N

Department Innere Medizin/Klinik für Hämatologie, Onkologie und Rheumatologie, Heidelberg

author Polke Polke Markus M

Thoraxklinik Heidelberg gGmbH, Universitätsklinikum Heidelberg, Heidelberg

author Herth Herth Felix J. F. FJF

Thoraxklinik Heidelberg gGmbH, Universitätsklinikum Heidelberg, Heidelberg

author Merkt Merkt Wolfgang W

Department Innere Medizin/Klinik für Hämatologie, Onkologie und Rheumatologie, Heidelberg Universitätsklinikum Düsseldorf, Klinik für Rheumatologie, Düsseldorf

author Lorenz Lorenz Hanns-Martin HM

Department Innere Medizin/Klinik für Hämatologie, Onkologie und Rheumatologie, Heidelberg

author German Medical Science GMS Publishing House

Düsseldorf

610 20250917 engl This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). M0627 215 Deutsche Gesellschaft für Rheumatologie Deutsche Gesellschaft für Orthopädische Rheumatologie 53. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 39. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh) Deutscher Rheumatologiekongress 2025 Verschiedenes Wiesbaden 20250917 20250920 VS.04 TextIntroduction: Even if cardiac sarcoidosis occurs in only 5–10% of all cases with systemic sarcoidosis , it is associated with challenges in diagnosis, therapy and treatment follow-up as the majority of patients have multi-organ disease and immunosuppressive treatment mostly relies on case series and individual expert decisions . Therefore, the present study shall provide more comprehensive and comparing data supporting the use of conventional synthetic (cs-) and biologic (b-) disease-modifying anti-rheumatic drugs (DMARD) in the treatment of cardiac sarcoidosis.Methods: In total, 35 patients with cardiac sarcoidosis meeting the definite or highly probable diagnostic criteria of both Heart Rhythm Society (HRS) and Japanese Cardiology Society (JCS) were analyzed retrospectively. Both clinical, laboratory and echocardiographic parameters as well as adverse events of the given therapy were compared before and 3-6 months after initiating immunosuppressive treatment of active cardiac sarcoidosis with either azathioprine, methotrexate, cyclophosphamide or infliximab.Results: After 3–6 months, immunosuppressive treatment with azathioprine, methotrexate, cyclophosphamide and infliximab showed significant increase of left ventricular ejection fraction in echocardiography. Values of N-terminal pro-B-type natriuretic peptide, troponin T, soluble interleukin-2-receptor and c-reactive protein were initially increased and showed a significant decrease under treatment. Patients’ and physicians’ global assessment revealed a stable or improved overall clinical function. Dose of prednisolone could be tapered significantly. Adverse events occurred only in a small number of patients.Conclusion: Our data support treatment of cardiac sarcoidosis with both csDMARD and bDMARD leading to an improved cardiac function, decreased disease activity parameters and stable or improved overall clinical disease burden, significantly reduced dose of administered prednisolone accompanied with few adverse events.Disclosures: There was no conflict of interest of any of the authors. Kouranos V Sharma R Cardiac sarcoidosis: state-of-the-art review 2021 Heart 1591-9 Kouranos V, Sharma R. Cardiac sarcoidosis: state-of-the-art review. Heart. 2021 Oct;107(19):1591-9. DOI: 10.1136/heartjnl-2019-316442 http://dx.doi.org/10.1136/heartjnl-2019-316442 Lehtonen J Uusitalo V Pöyhönen P Mäyränpää MI Kupari M Cardiac sarcoidosis: phenotypes, diagnosis, treatment, and prognosis 2023 Eur Heart J 1495-510 Lehtonen J, Uusitalo V, Pöyhönen P, Mäyränpää MI, Kupari M. Cardiac sarcoidosis: phenotypes, diagnosis, treatment, and prognosis. Eur Heart J. 2023 May 1;44(17):1495-510. DOI: 10.1093/eurheartj/ehad067 http://dx.doi.org/10.1093/eurheartj/ehad067 0 0 0 0